With the growing social and economic impact of dementia on the society, emphasis is shifting from eariy diagnosis and treatment to prevention of cognitive impairment and dementia. The neuroprotective effects shown in animal models and cell cultures suggest that estrogen might be used in the prevention or delay of cognitive impairment and dementia in postmenopausal women. However, estrogen used as a menopausal hormone treatment (MHT) in older (i.e., not newly menopausal) women did not prevent dementia, and controversy exists about whether MHT containing estrogen can preserve neurologic function and decrease the risk of dementia when administered eariy in menopause. In this proposal, we will assess the neuroprotective effects of MHT on cognitive performance and surrogate brain imaging markers. This project leverages the existing cohort of women who participated in the Kronos Eariy Estrogen Prevention Study (KEEPS) who were treated with either oral conjugated equine estrogen ortransdremal 17(3 estradiol or with a placebo eariy in menopause, which is considered the critical """"""""window of opportunity"""""""" for estrogen treatment. In addition to cognitive testing (through Core B), we will consider several imaging markers of brain. First is """"""""C-Pittsburgh Compound B (PiB) retention on positron emission tomography;this is a surrogate marker for p-amyloid pathology of Alzheimer's disease (AD). Second is the change in white-matter hyperintensity load on MRI over 7 years after randomization;this is a surrogate marker for ischemic white-matter disease. Third is change in brain volume indices on MRI over 7 years after randomization;this is a surrogate marker for neuronal degeneration. Each imaging marker should provide independent information on the common pathologic features associated with cognitive health in older adults. This project addresses an important and controversial aspect of MHT by determining whether therapy in the immediate postmenopausal years preserves cognition and neuronal integrity. Since participants will also undergo assessment of cerebral microvascular dilatory capacity and characterization of platelet and blood-borne microvesicles in Project III, insight will be gained into mechanisms which might impact progression of AD-related pathology. Collectively, findings from this study have the potential to significantly advance scientific knowledge and clinical practice by providing insight into effects of MHT on cognitive health eariy in menopause. Our findings will help patients and physicians make informed decisions regarding the benefit and risk of such treatments.

Public Health Relevance

This study has the potential to change preventive interventions for dementia in aging women. Identification of neuroprotective effects of estrogen therapy would have a significant influence on women deciding whether to use hormonal treatments during the transition into menopause and in the eariy postmenopausal years.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG044170-03
Application #
8733124
Study Section
Special Emphasis Panel (ZRG1-EMNR-Q)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
3
Fiscal Year
2014
Total Cost
$189,055
Indirect Cost
$60,958
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kantarci, Kejal; Lowe, Val J; Boeve, Bradley F et al. (2017) AV-1451 tau and ?-amyloid positron emission tomography imaging in dementia with Lewy bodies. Ann Neurol 81:58-67
Fields, Julie A; Garovic, Vesna D; Mielke, Michelle M et al. (2017) Preeclampsia and cognitive impairment later in life. Am J Obstet Gynecol 217:74.e1-74.e11
Jayachandran, Muthuvel; Garovic, Vesna D; Mielke, Michelle M et al. (2017) Characterization of intravascular cellular activation in relationship to subclinical atherosclerosis in postmenopausal women. PLoS One 12:e0183159
Rocca, Walter A; Gazzuola Rocca, Liliana; Smith, Carin Y et al. (2017) Cohort profile: the Mayo Clinic Cohort Study of Oophorectomy and Aging-2 (MOA-2) in Olmsted County, Minnesota (USA). BMJ Open 7:e018861
Ranadive, Sushant M; Harvey, Ronee E; Lahr, Brian D et al. (2017) Sympathetic responsiveness is not increased in women with a history of hypertensive pregnancy. Am J Physiol Regul Integr Comp Physiol 312:R49-R54
Raman, Mekala R; Shu, Yunhong; Lesnick, Timothy G et al. (2017) Regional T1 relaxation time constants in Ex vivo human brain: Longitudinal effects of formalin exposure. Magn Reson Med 77:774-778
Sarro, Lidia; Tosakulwong, Nirubol; Schwarz, Christopher G et al. (2017) An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Dement 13:257-266
Rocca, Walter A; Savica, Rodolfo; Grossardt, Brandon R (2017) Response to Letter by Friedman on ""Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study"". Mov Disord 32:1111-1112
Milic, N M; Milin-Lazovic, J; Weissgerber, T L et al. (2017) Preclinical atherosclerosis at the time of pre-eclamptic pregnancy and up to 10 years postpartum: systematic review and meta-analysis. Ultrasound Obstet Gynecol 49:110-115
Cintron, Dahima; Lipford, Melissa; Larrea-Mantilla, Laura et al. (2017) Efficacy of menopausal hormone therapy on sleep quality: systematic review and meta-analysis. Endocrine 55:702-711

Showing the most recent 10 out of 138 publications